Pharmaceuticals

23andMe (NASDAQ: ME): Bankruptcy Filing and Strategic Sale Process

23andMe has filed for Chapter 11 to maximize business value while facing a steep decline, leadership change, and investment risks surrounding genetics.

Alnylam Pharmaceuticals Stock (ALNY): Innovative Treatment for ATTR Amyloidosis

Alnylam Pharmaceuticals gains FDA approval for AMVUTTRA, marking a milestone in the fight against ATTR amyloidosis with effective treatment options.

3 US Healthcare Stocks That Might Be Undervalued 2025

Healthcare is showing strength in a shaky market—discover which overlooked U.S. stocks could potentially offer upside as the sector regains investor attention.

Medicus Pharma Share Price: MDCX Stock Closed Up 15.35%

Medicus Pharma Share Price Soars: Medicus Pharma closed yesterday at $3.4950, up 15.35% from the previous close of $3.03. Find out all you need to know.

Advancing Oncology: Innovations in Treatment and Detection

Oncology is advancing with AI, biologics, and non-invasive treatments. See how AstraZeneca, Roche, AbbVie, and Medicus Pharma are leading the way.

See Why Some Investors Are Watching This Biotech Company

Innovation in healthcare is not just about science. It’s also about the patient experience. One small company is developing a unique treatment.

Haleon (HLN): Pfizer Sells Stake in Consumer Healthcare Firm

Pfizer has finalized its exit from Haleon by selling its remaining stake for £2.5 billion, marking a significant milestone for the firm.

Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts

Gilead Sciences shares fall amid reports of potential federal funding cuts for HIV initiatives, raising concerns for investors.

Biotech Stock Tapping $7B+ Skin Cancer Market Opportunity

Medicus Pharma (NASDAQ: MDCX) is revolutionizing skin cancer treatment with a non-invasive microneedle patch, tapping into a $7B market opportunity. Discover more.

AstraZeneca Stock (AZN): Transformative Acquisition in Cancer Care

AstraZeneca acquires EsoBiotec for up to $1 billion, enhancing its cancer treatment portfolio with innovative cell therapies.

The Biotech Stocks Tackling the World’s Most Common Cancer

Medicus Pharma (NASDAQ: MDCX) joins Roche, Regeneron, and Bristol-Myers in the 360i BCC market matrix. Discover its breakthrough innovation in skin cancer care.

KalVista Pharmaceuticals Stock (KALV): Advancements in HAE Treatment and Regulatory Progress

KalVista announces promising third quarter results with sebetralstat's progress, pivotal for patients with hereditary angioedema.

TG Therapeutics Stock (TGTX): Advancing MS Treatment

TG Therapeutics announces key data presentations on BRIUMVI, its MS treatment, signaling growth potential for investors.

Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline

Enliven Therapeutics continues to progress in its oncology trials with key Phase 1 data readouts expected in 2025 and a strong cash runway into 2027—discover the latest updates now.

Mineralys Therapeutics Stock (MLYS): Strategic Offering to Fuel Growth

Mineralys Therapeutics has priced a public offering to raise $175 million to advance clinical development of innovative treatments.